Impact Therapeutics scores $30 mln Series C
China-based Impact Therapeutics Inc, a developer of medicine that treats cancer and other life-threatening diseases, has closed $30 million in Series C financing. Decheng Capital led the round with participation from return backer Lilly Asian Ventures.
3 August 2018•1 min read
